LINICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 428 JPY | -0.23% |
|
+6.20% | -19.25% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.47 for the 2024 fiscal year.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past twelve months, EPS forecast has been revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The firm trades with high earnings multiples: 31.54 times its 2024 earnings per share.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -19.25% | 60.3M | - | ||
| +22.52% | 46.93B | B- | ||
| +36.98% | 39.08B | A | ||
| -8.73% | 38.48B | B | ||
| +28.09% | 31.01B | B | ||
| -12.26% | 26.14B | C | ||
| +10.57% | 25.88B | B- | ||
| +32.23% | 12.53B | C+ | ||
| -6.56% | 11.36B | B+ | ||
| -13.11% | 10.65B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2183 Stock
- Ratings Linical Co., Ltd.
